Insider Trading Arrangements |
3 Months Ended |
|---|---|
|
Mar. 31, 2026
shares
| |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | Rule 10b5-1 Trading Plans On March 20, 2026, Daniel Long, D.Phil., our Senior Vice President, Drug Discovery, adopted a pre-arranged trading plan for the sale, at the times and prices specified in the plan, of up to an aggregate of 45,000 shares of our common stock (comprised of shares issuable upon the exercise of option awards previously granted to Dr. Long), which plan expires at the earlier of March 31, 2027 and the date upon which all authorized transactions thereunder are completed. Dr. Long's trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. During the three months ended March 31, 2026, no other directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) of the Company adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” as each term is defined in Item 408 of Regulation S-K. |
| Rule 10b5-1 Arrangement Adopted | false |
| Non-Rule 10b5-1 Arrangement Adopted | false |
| Rule 10b5-1 Arrangement Terminated | false |
| Non-Rule 10b5-1 Arrangement Terminated | false |
| Rule 10b5 1Arr Modified Flag | false |
| Non Rule 10b5 1 Arr Modified Flag | false |
| Daniel Long | |
| Trading Arrangements, by Individual | |
| Name | Daniel Long |
| Title | Senior Vice President |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | March 20, 2026 |
| Aggregate Available | 45,000 |